<DOC>
	<DOCNO>NCT00731692</DOCNO>
	<brief_summary>The purpose study evaluate whether FTY720 effective delaying MS disability progression compare placebo patient PPMS .</brief_summary>
	<brief_title>FTY720 Patients With Primary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>General 1. sign write informed consent prior participate study 2 . 25 65 year age inclusive 3. female childbearing potential must : negative pregnancy test Baseline ( prior randomization ) use simultaneously two form effective contraception treatment 3months discontinuation study medication Primary Progressive Multiple sclerosis . 1. diagnosis primary progressive multiple sclerosis ( accord 2005 Revised McDonald criterion ) : 2. time since first report symptom 2 10 year 3. evidence clinical disability progression 2 year prior Screening 4. disability status Screening EDSS score 3.56.0 inclusive pyramidal functional system score 2 25'TWT less 30 second PPMS specific : History relapses/attacks Progressive neurological disorder PPMS Pure cerebellar syndrome pure visual progressive syndrome pure cognitive progressive syndrome Presence spinal cord compression screen MRI Relevant history vitamin B12 deficit Evidence syphilis borreliosis Screening Cardiovascular condition : Myocardial infarction within past 6 month current unstable ischemic heart disease History angina pectoris due coronary spasm history Raynaud 's phenomenon Severe cardiac failure cardiac arrest History symptomatic bradycardia Resting pulse &lt; 55 bpm predose History sick sinus syndrome sinoatrial heart block History presence second third degree AV block increase QT interval ( QTc &gt; 440 m ) Arrythmia require treatment class III antiarrythmic drug History positive tilt test workout vasovagal syncope Hypertension , control medication Pulmonary : Severe respiratory disease pulmonary fibrosis TB Abnormal Xray , suggestive active pulmonary disease Abnormal PFT : &lt; 70 % predict FEV1 FVC ; &lt; 60 % DLCO Patients receive chronic ( daily ) therapy asthma Hepatic : Known history alcohol abuse , chronic liver biliary disease Total conjugate Brb &gt; ULN , unless context Gilbert 's syndrome AP &gt; 1.5xULN ; ALT/AST &gt; 2xULN ; GGT &gt; 3xULN Other : History chronic disease immune system MS Malignancy ( successfully treat SCC BCC ) Diabetes Mellitus Macular Edema present screen HIV , Hepatitis C B , active infection History total lymphoid irradiation bone marrow transplantation Serum creatinine &gt; 1.7 mg/dl WBC &lt; 3500 cells/mm3 Lymphocyte count &lt; 800 cells/mm3 History substance abuse factor may interfere subject ability cooperate comply study procedure Unable undergo MRI scan Participation therapeutical clinical research study 6 month prior randomization Pregnant lactate woman Drugs require washout period : 3 month : Systemic corticosteroid ACTH INFbeta 6 month : Immunosuppressive medication Immunoglobulins Monoclonal antibody Drugs exclude participation study : Cladribine Cyclophosphamide Mitoxantrone ( except : patient receive cumulative dose 60mg/m2 5 year ago could enter study ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>FTY720 , primary progressive multiple sclerosis , PPMS</keyword>
</DOC>